JAZZ

Jazz Pharmaceuticals is a profitable cash machine masquerading, for one year, as a loss-maker. FY2025 revenue grew 4.9% to $4.27B — the fifth straight year of growth from $3.09B in FY2021 — on a genuinely diversified rare-disease and oncology portfolio: Xywav and Epidiolex in sleep and epilepsy, plus a widening oncology franchise (Zepzelca in SCLC, Ziihera in HER2+ biliary cancer, and the newly launched Modeyso and Rylaze). Critically, operating cash flow held at $1.36B (down just 2.9%), so the business is generating substantial real cash even though it reported a -$356M net loss and -$5.84 diluted EPS.

The GAAP loss — a swing from +$560M net income in FY2024 — is a sharp reversal but is almost certainly driven by non-cash items (acquired IPR&D, intangible amortization or impairment tied to its in-licensing and M&A strategy), given that operating cash flow barely moved and the company describes evaluating 'a wide array of strategic transactions.' That makes the trailing P/E of -38.5x meaningless; the right lens is the ~10x operating cash flow the $13.8B market cap implies, which is cheap if the cash generation persists.